The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Companies Mentioned Include:
- Advinus Therapeutics Ltd
- Akarna Therapeutics Ltd.
- Angion Biomedica Corp.
- Asubio Pharma Co., Ltd.
- aTyr Pharma, Inc.
- Beijing Kawin Technology Share-Holding Co., Ltd.
- BioLineRx, Ltd.
- Bioneer Corporation
- BiOrion Technologies B.V.
- Bird Rock Bio, Inc.
- Bristol-Myers Squibb Company
- Cellmid Limited
- ContraVir Pharmaceuticals, Inc.
- Dicerna Pharmaceuticals, Inc.
- Digna Biotech, S.L.
- Dr. Falk Pharma GmbH
- Dynavax Technologies Corporation
- Evotec AG
- Galectin Therapeutics, Inc.
- Genfit SA
- Ribomic Inc.
- RXi Pharmaceuticals Corporation
- Silence Therapeutics Plc
- TCM Biotech International Corp
- Vascular Biogenics Ltd.
- Virobay Inc.
- XTuit Pharmaceuticals, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/g8qnxs/liver_fibrosis